Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity.
Alzheimer’s disease
Down syndrome
Exosome
Extracellular vesicle
Long-term potentiation
MAO-B
Microvesicle
Mitochondria
Mitovesicle
Neurodegenerative disease
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
14 Apr 2024
14 Apr 2024
Historique:
received:
31
08
2023
accepted:
18
03
2024
medline:
15
4
2024
pubmed:
15
4
2024
entrez:
14
4
2024
Statut:
epublish
Résumé
Hypometabolism tied to mitochondrial dysfunction occurs in the aging brain and in neurodegenerative disorders, including in Alzheimer's disease, in Down syndrome, and in mouse models of these conditions. We have previously shown that mitovesicles, small extracellular vesicles (EVs) of mitochondrial origin, are altered in content and abundance in multiple brain conditions characterized by mitochondrial dysfunction. However, given their recent discovery, it is yet to be explored what mitovesicles regulate and modify, both under physiological conditions and in the diseased brain. In this study, we investigated the effects of mitovesicles on synaptic function, and the molecular players involved. Hippocampal slices from wild-type mice were perfused with the three known types of EVs, mitovesicles, microvesicles, or exosomes, isolated from the brain of a mouse model of Down syndrome or of a diploid control and long-term potentiation (LTP) recorded. The role of the monoamine oxidases type B (MAO-B) and type A (MAO-A) in mitovesicle-driven LTP impairments was addressed by treatment of mitovesicles with the irreversible MAO inhibitors pargyline and clorgiline prior to perfusion of the hippocampal slices. Mitovesicles from the brain of the Down syndrome model reduced LTP within minutes of mitovesicle addition. Mitovesicles isolated from control brains did not trigger electrophysiological effects, nor did other types of brain EVs (microvesicles and exosomes) from any genotype tested. Depleting mitovesicles of their MAO-B, but not MAO-A, activity eliminated their ability to alter LTP. Mitovesicle impairment of LTP is a previously undescribed paracrine-like mechanism by which EVs modulate synaptic activity, demonstrating that mitovesicles are active participants in the propagation of cellular and functional homeostatic changes in the context of neurodegenerative disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Hypometabolism tied to mitochondrial dysfunction occurs in the aging brain and in neurodegenerative disorders, including in Alzheimer's disease, in Down syndrome, and in mouse models of these conditions. We have previously shown that mitovesicles, small extracellular vesicles (EVs) of mitochondrial origin, are altered in content and abundance in multiple brain conditions characterized by mitochondrial dysfunction. However, given their recent discovery, it is yet to be explored what mitovesicles regulate and modify, both under physiological conditions and in the diseased brain. In this study, we investigated the effects of mitovesicles on synaptic function, and the molecular players involved.
METHODS
METHODS
Hippocampal slices from wild-type mice were perfused with the three known types of EVs, mitovesicles, microvesicles, or exosomes, isolated from the brain of a mouse model of Down syndrome or of a diploid control and long-term potentiation (LTP) recorded. The role of the monoamine oxidases type B (MAO-B) and type A (MAO-A) in mitovesicle-driven LTP impairments was addressed by treatment of mitovesicles with the irreversible MAO inhibitors pargyline and clorgiline prior to perfusion of the hippocampal slices.
RESULTS
RESULTS
Mitovesicles from the brain of the Down syndrome model reduced LTP within minutes of mitovesicle addition. Mitovesicles isolated from control brains did not trigger electrophysiological effects, nor did other types of brain EVs (microvesicles and exosomes) from any genotype tested. Depleting mitovesicles of their MAO-B, but not MAO-A, activity eliminated their ability to alter LTP.
CONCLUSIONS
CONCLUSIONS
Mitovesicle impairment of LTP is a previously undescribed paracrine-like mechanism by which EVs modulate synaptic activity, demonstrating that mitovesicles are active participants in the propagation of cellular and functional homeostatic changes in the context of neurodegenerative disorders.
Identifiants
pubmed: 38616258
doi: 10.1186/s13024-024-00721-z
pii: 10.1186/s13024-024-00721-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Subventions
Organisme : NIA NIH HHS
ID : AG017617
Pays : United States
Organisme : NIA NIH HHS
ID : AG056732
Pays : United States
Organisme : NIA NIH HHS
ID : AG057517
Pays : United States
Organisme : NIDA NIH HHS
ID : DA044489
Pays : United States
Organisme : NIH HHS
ID : R01NS110024
Pays : United States
Organisme : Alzheimer's Association
ID : AARF-22-923826
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213–28.
pubmed: 29339798
doi: 10.1038/nrm.2017.125
D’Acunzo P, Perez-Gonzalez R, Kim Y, Hargash T, Miller C, Alldred MJ, Erdjument-Bromage H, Penikalapati SC, Pawlik M, Saito M et al. Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome. Sci Adv 2021, 7.
Perez-Gonzalez R, Gauthier SA, Kumar A, Levy E. The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space. J Biol Chem. 2012;287:43108–15.
pubmed: 23129776
pmcid: 3522305
doi: 10.1074/jbc.M112.404467
Gauthier SA, Perez-Gonzalez R, Sharma A, Huang FK, Alldred MJ, Pawlik M, Kaur G, Ginsberg SD, Neubert TA, Levy E. Enhanced exosome secretion in Down syndrome brain - a protective mechanism to alleviate neuronal endosomal abnormalities. Acta Neuropathol Commun. 2017;5:65.
pubmed: 28851452
pmcid: 5576289
doi: 10.1186/s40478-017-0466-0
Kim Y, Perez-Gonzalez R, Miller C, Kurz M, D’Acunzo P, Goulbourne CN, Levy E. Sex differentially alters secretion of Brain Extracellular vesicles during aging: a potential mechanism for maintaining Brain Homeostasis. Neurochem Res. 2022;47:3428–39.
pubmed: 35904699
pmcid: 9546961
doi: 10.1007/s11064-022-03701-1
Barreto BR, D’Acunzo P, Ungania JM, Das S, Hashim A, Goulbourne CN, Canals-Baker S, Saito M, Saito M, Sershen H, Levy E. Cocaine modulates the neuronal endosomal system and extracellular vesicles in a sex-dependent manner. Neurochem Res. 2022;47:2263–77.
pubmed: 35501523
pmcid: 9352616
doi: 10.1007/s11064-022-03612-1
Zhang Y, Varela L, Szigeti-Buck K, Williams A, Stoiljkovic M, Sestan-Pesa M, Henao-Mejia J, D’Acunzo P, Levy E, Flavell RA, et al. Cerebellar Kv3.3 potassium channels activate TANK-binding kinase 1 to regulate trafficking of the cell survival protein Hax-1. Nat Commun. 2021;12:1731.
pubmed: 33741962
pmcid: 7979925
doi: 10.1038/s41467-021-22003-8
D’Acunzo P, Kim Y, Ungania JM, Perez-Gonzalez R, Goulbourne CN, Levy E. Isolation of mitochondria-derived mitovesicles and subpopulations of microvesicles and exosomes from brain tissues. Nat Protoc. 2022;17:2517–49.
pubmed: 35962195
pmcid: 9633367
doi: 10.1038/s41596-022-00719-1
D’Acunzo P, Ungania JM, Kim Y, Barreto BR, DeRosa S, Pawlik M, Canals-Baker S, Erdjument-Bromage H, Hashim A, Goulbourne CN, et al. Cocaine perturbs mitovesicle biology in the brain. J Extracell Vesicles. 2023;12:e12301.
pubmed: 36691887
pmcid: 9871795
doi: 10.1002/jev2.12301
D’Acunzo P, Hargash T, Pawlik M, Goulbourne CN, Perez-Gonzalez R, Levy E. Enhanced generation of intraluminal vesicles in neuronal late endosomes in the brain of a Down syndrome mouse model with endosomal dysfunction. Dev Neurobiol. 2019;79:656–63.
pubmed: 31278881
pmcid: 6894426
doi: 10.1002/dneu.22708
Crewe C, Funcke JB, Li S, Joffin N, Gliniak CM, Ghaben AL, An YA, Sadek HA, Gordillo R, Akgul Y, et al. Extracellular vesicle-based interorgan transport of mitochondria from energetically stressed adipocytes. Cell Metab. 2021;33:1853–e18681811.
pubmed: 34418352
pmcid: 8429176
doi: 10.1016/j.cmet.2021.08.002
Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, Stolz DB, Watkins SC, Di YP, Leikauf GD, et al. Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015;6:8472.
pubmed: 26442449
doi: 10.1038/ncomms9472
Jang SC, Crescitelli R, Cvjetkovic A, Belgrano V, Olofsson Bagge R, Sundfeldt K, Ochiya T, Kalluri R, Lotvall J. Mitochondrial protein enriched extracellular vesicles discovered in human melanoma tissues can be detected in patient plasma. J Extracell Vesicles. 2019;8:1635420.
pubmed: 31497264
pmcid: 6719261
doi: 10.1080/20013078.2019.1635420
Puhm F, Afonyushkin T, Resch U, Obermayer G, Rohde M, Penz T, Schuster M, Wagner G, Rendeiro AF, Melki I, et al. Mitochondria are a subset of Extracellular vesicles released by activated monocytes and induce type I IFN and TNF responses in endothelial cells. Circ Res. 2019;125:43–52.
pubmed: 31219742
doi: 10.1161/CIRCRESAHA.118.314601
Jakobs S, Stephan T, Ilgen P, Bruser C. Light Microscopy of Mitochondria at the Nanoscale. Annu Rev Biophys. 2020;49:289–308.
pubmed: 32092283
pmcid: 7610798
doi: 10.1146/annurev-biophys-121219-081550
Kuhlbrandt W. Structure and function of mitochondrial membrane protein complexes. BMC Biol. 2015;13:89.
pubmed: 26515107
pmcid: 4625866
doi: 10.1186/s12915-015-0201-x
Hauptmann N, Grimsby J, Shih JC, Cadenas E. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys. 1996;335:295–304.
pubmed: 8914926
doi: 10.1006/abbi.1996.0510
Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, Guttman M, Hornykiewicz O, Kish SJ. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders. Brain. 2017;140:2460–74.
pubmed: 29050386
pmcid: 6669411
doi: 10.1093/brain/awx172
Park JH, Ju YH, Choi JW, Song HJ, Jang BK, Woo J, Chun H, Kim HJ, Shin SJ, Yarishkin O, et al. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Sci Adv. 2019;5:eaav0316.
pubmed: 30906861
pmcid: 6426469
doi: 10.1126/sciadv.aav0316
Schedin-Weiss S, Inoue M, Hromadkova L, Teranishi Y, Yamamoto NG, Wiehager B, Bogdanovic N, Winblad B, Sandebring-Matton A, Frykman S, Tjernberg LO. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with gamma-secretase and regulates neuronal amyloid beta-peptide levels. Alzheimers Res Ther. 2017;9:57.
pubmed: 28764767
pmcid: 5540560
doi: 10.1186/s13195-017-0279-1
Meyer JH, Braga J. Development and clinical application of Positron Emission Tomography Imaging agents for Monoamine Oxidase B. Front Neurosci. 2021;15:773404.
pubmed: 35280341
doi: 10.3389/fnins.2021.773404
Coskun PE, Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, Wallace DC. Systemic mitochondrial dysfunction and the etiology of Alzheimer’s disease and down syndrome dementia. J Alzheimers Dis. 2010;20(Suppl 2):S293–310.
pubmed: 20463402
pmcid: 4175722
doi: 10.3233/JAD-2010-100351
Bordi M, Darji S, Sato Y, Mellen M, Berg MJ, Kumar A, Jiang Y, Nixon RA. mTOR hyperactivation in Down Syndrome underlies deficits in autophagy induction, autophagosome formation, and mitophagy. Cell Death Dis. 2019;10:563.
pubmed: 31332166
pmcid: 6646359
doi: 10.1038/s41419-019-1752-5
Caracausi M, Ghini V, Locatelli C, Mericio M, Piovesan A, Antonaros F, Pelleri MC, Vitale L, Vacca RA, Bedetti F, et al. Plasma and urinary metabolomic profiles of Down syndrome correlate with alteration of mitochondrial metabolism. Sci Rep. 2018;8:2977.
pubmed: 29445163
pmcid: 5813015
doi: 10.1038/s41598-018-20834-y
Mapstone M, Gross TJ, Macciardi F, Cheema AK, Petersen M, Head E, Handen BL, Klunk WE, Christian BT, Silverman W, et al. Metabolic correlates of prevalent mild cognitive impairment and Alzheimer’s disease in adults with Down syndrome. Alzheimers Dement (Amst). 2020;12:e12028.
pubmed: 32258359
Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, Lingford-Hughes A, Huiban M, Passchier J, Rowe JB, et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease. Sci Transl Med. 2022;14:eabk1051.
pubmed: 35976998
doi: 10.1126/scitranslmed.abk1051
Alldred MJ, Lee SH, Stutzmann GE, Ginsberg SD. Oxidative phosphorylation is dysregulated within the Basocortical Circuit in a 6-month old mouse model of Down Syndrome and Alzheimer’s Disease. Front Aging Neurosci. 2021;13:707950.
pubmed: 34489678
pmcid: 8417045
doi: 10.3389/fnagi.2021.707950
Villar AJ, Belichenko PV, Gillespie AM, Kozy HM, Mobley WC, Epstein CJ. Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm Genome. 2005;16:79–90.
pubmed: 15859352
doi: 10.1007/s00335-004-2428-7
e ShiftC,..Welsh JA, Goberdhan DC, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TA, Erdbrügger U, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;2:e12404.
doi: 10.1002/jev2.12404
Mathews PM, Guerra CB, Jiang Y, Grbovic OM, Kao BH, Schmidt SD, Dinakar R, Mercken M, Hille-Rehfeld A, Rohrer J, et al. Alzheimer’s disease-related overexpression of the cation-dependent mannose 6-phosphate receptor increases Abeta secretion: role for altered lysosomal hydrolase distribution in beta-amyloidogenesis. J Biol Chem. 2002;277:5299–307.
pubmed: 11551970
doi: 10.1074/jbc.M108161200
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.
pubmed: 22930834
pmcid: 5554542
doi: 10.1038/nmeth.2089
Fa M, Staniszewski A, Saeed F, Francis YI, Arancio O. Dynamin 1 is required for memory formation. PLoS ONE. 2014;9:e91954.
pubmed: 24643165
pmcid: 3958425
doi: 10.1371/journal.pone.0091954
McVey MJ, Spring CM, Kuebler WM. Improved resolution in extracellular vesicle populations using 405 instead of 488 nm side scatter. J Extracell Vesicles. 2018;7:1454776.
pubmed: 29696076
pmcid: 5912191
doi: 10.1080/20013078.2018.1454776
Welsh JA, Van Der Pol E, Arkesteijn GJA, Bremer M, Brisson A, Coumans F, Dignat-George F, Duggan E, Ghiran I, Giebel B, et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J Extracell Vesicles. 2020;9:1713526.
pubmed: 32128070
pmcid: 7034442
doi: 10.1080/20013078.2020.1713526
Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, Mihara K. Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells. J Cell Biol. 2010;191:1141–58.
pubmed: 21149567
pmcid: 3002033
doi: 10.1083/jcb.201007152
Fecher C, Trovo L, Muller SA, Snaidero N, Wettmarshausen J, Heink S, Ortiz O, Wagner I, Kuhn R, Hartmann J, et al. Cell-type-specific profiling of brain mitochondria reveals functional and molecular diversity. Nat Neurosci. 2019;22:1731–42.
pubmed: 31501572
doi: 10.1038/s41593-019-0479-z
Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science. 1985;230:181–3.
pubmed: 3875898
doi: 10.1126/science.3875898
Freeman MR, Rowitch DH. Evolving concepts of gliogenesis: a look way back and ahead to the next 25 years. Neuron. 2013;80:613–23.
pubmed: 24183014
pmcid: 5221505
doi: 10.1016/j.neuron.2013.10.034
Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol. 2016;7:340.
pubmed: 27803666
pmcid: 5067815
doi: 10.3389/fphar.2016.00340
Izzo A, Mollo N, Nitti M, Paladino S, Cali G, Genesio R, Bonfiglio F, Cicatiello R, Barbato M, Sarnataro V, et al. Mitochondrial dysfunction in down syndrome: molecular mechanisms and therapeutic targets. Mol Med. 2018;24:2.
pubmed: 30134785
pmcid: 6016872
doi: 10.1186/s10020-018-0004-y
Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol. 1985;17:278–82.
pubmed: 3158266
doi: 10.1002/ana.410170310
Kukreja L, Kujoth GC, Prolla TA, Van Leuven F, Vassar R. Increased mtDNA mutations with aging promotes amyloid accumulation and brain atrophy in the APP/Ld transgenic mouse model of Alzheimer’s disease. Mol Neurodegener. 2014;9:16.
pubmed: 24885175
pmcid: 4028006
doi: 10.1186/1750-1326-9-16
Sweetat S, Nitzan K, Suissa N, Haimovich Y, Lichtenstein M, Zabit S, Benhamron S, Akarieh K, Mishra K, Barasch D et al. The Beneficial Effect of Mitochondrial Transfer Therapy in 5XFAD Mice via Liver-Serum-Brain Response. Cells: 2023, 12.
Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer’s disease. J Neural Transm Gen Sect. 1993;91:135–59.
pubmed: 8099796
doi: 10.1007/BF01245229
Quartey MO, Nyarko JNK, Pennington PR, Heistad RM, Klassen PC, Baker GB, Mousseau DD. Alzheimer Disease and selected risk factors disrupt a co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but not in the cortex. Front Neurosci. 2018;12:419.
pubmed: 29997470
pmcid: 6029266
doi: 10.3389/fnins.2018.00419
Whittle N, Sartori SB, Dierssen M, Lubec G, Singewald N. Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics. 2007;120:e1465–1471.
pubmed: 17998315
doi: 10.1542/peds.2006-3448
Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M. Alzheimer-like neurotransmitter deficits in adult down’s syndrome brain tissue. J Neurol Neurosurg Psychiatry. 1987;50:775–8.
pubmed: 2440994
pmcid: 1032086
doi: 10.1136/jnnp.50.6.775
Dekker AD, Vermeiren Y, Albac C, Lana-Elola E, Watson-Scales S, Gibbins D, Aerts T, Van Dam D, Fisher EMC, Tybulewicz VLJ, et al. Aging rather than aneuploidy affects monoamine neurotransmitters in brain regions of Down syndrome mouse models. Neurobiol Dis. 2017;105:235–44.
pubmed: 28624415
pmcid: 5536154
doi: 10.1016/j.nbd.2017.06.007
Singh C, Bortolato M, Bali N, Godar SC, Scott AL, Chen K, Thompson RF, Shih JC. Cognitive abnormalities and hippocampal alterations in monoamine oxidase A and B knockout mice. Proc Natl Acad Sci U S A. 2013;110:12816–21.
pubmed: 23858446
pmcid: 3732950
doi: 10.1073/pnas.1308037110
Perez-Gonzalez R, Kim Y, Miller C, Pacheco-Quinto J, Eckman EA, Levy E. Extracellular vesicles: where the amyloid precursor protein carboxyl-terminal fragments accumulate and amyloid-beta oligomerizes. FASEB J. 2020;34:12922–31.
pubmed: 32772431
doi: 10.1096/fj.202000823R
Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, Wong PC. BACE1 is the major beta-secretase for generation of abeta peptides by neurons. Nat Neurosci. 2001;4:233–4.
pubmed: 11224536
doi: 10.1038/85064
Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer’s disease. Science. 1987;235:873–7.
pubmed: 3544219
doi: 10.1126/science.3544219
Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent a beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007;282:22707–20.
pubmed: 17556372
doi: 10.1074/jbc.M611050200
Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet. 1995;11:177–84.
pubmed: 7550346
doi: 10.1038/ng1095-177
Choi JH, Berger JD, Mazzella MJ, Morales-Corraliza J, Cataldo AM, Nixon RA, Ginsberg SD, Levy E, Mathews PM. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn down syndrome mouse model. J Neurochem. 2009;110:1818–27.
pubmed: 19619138
pmcid: 2744432
doi: 10.1111/j.1471-4159.2009.06277.x
Kaur G, Sharma A, Xu W, Gerum S, Alldred MJ, Subbanna S, Basavarajappa BS, Pawlik M, Ohno M, Ginsberg SD, et al. Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down’s syndrome. J Neurosci. 2014;34:5099–106.
pubmed: 24719089
pmcid: 3983795
doi: 10.1523/JNEUROSCI.5338-13.2014